Abstract:Background: Most randomized controlled trials with a time-to-event outcome are designed assuming proportional hazards (PH) of the treatment effect. The sample size calculation is based on a logrank test. However, non-proportional hazards are increasingly common. At analysis, the estimated hazards ratio with a confidence interval is usually presented. The estimate is often obtained from a Cox PH model with treatment as a covariate. If non-proportional hazards are present, the logrank and equivalent Cox tests may lose power. To safeguard power, we previously suggested a 'joint test' combining the Cox test with a test of non-proportional hazards. Unfortunately, a larger sample size is needed to preserve power under PH. Here, we describe a novel test that unites the Cox test with a permutation test based on restricted mean survival time. Methods: We propose a combined hypothesis test based on a permutation test of the difference in restricted mean survival time across time. The test involves the minimum of the Cox and permutation test P-values. We approximate its null distribution and correct it for correlation between the two P-values. Using extensive simulations, we assess the type 1 error and power of the combined test under several scenarios and compare with other tests. We investigate powering a trial using the combined test. Results: The type 1 error of the combined test is close to nominal. Power under proportional hazards is slightly lower than for the Cox test. Enhanced power is available when the treatment difference shows an 'early effect', an initial separation of survival curves which diminishes over time. The power is reduced under a 'late effect', when little or no difference in survival curves is seen for an initial period and then a late separation occurs. We propose a method of powering a trial using the combined test. The 'insurance premium' offered by the combined test to safeguard power under non-PH represents about a single-digit percentage increase in sample size. Conclusions: The combined test increases trial power under an early treatment effect and protects power under other scenarios. Use of restricted mean survival time facilitates testing and displaying a generalized treatment effect.

Design and Analysis of Clinical Trials in the Presence of Delayed Treatment Effect

Adaptive Promising Zone Design for Cancer Immunotherapy with Heterogeneous Delayed Treatment Effect

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

Using Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

A Group Sequential Design and Sample Size Estimation for an Immunotherapy Trial with a Delayed Treatment Effect.

Nonparametric analysis of delayed treatment effects using single‐crossing constraints

Design and Analysis of group-sequential clinical trials based on a modestly-weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Group Sequential Design with Maximin Efficiency Robust Test for Immunotherapy with Generalized Delayed Treatment Effect.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

A Bayesian Piecewise Exponential Phase II Design for Monitoring a Time‐to‐event Endpoint

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy

The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves

A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome

A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart

Optimality of testing procedures for survival data

Covariate-adjusted Group Sequential Comparisons of Survival Probabilities

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis

Biomarker-Guided Adaptive Enrichment Design with Threshold Detection for Clinical Trials with Time-to-Event Outcome